Approval For UK Clinical Trial Announced By Oncolytics Biotech Inc.

Oncolytics Biotech Inc. (”Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN® in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. [click link for full article]

More: continued here

Filed under: Cancer on October 25th, 2007